NCT00629200View on ClinicalTrials.gov

Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 13, 2006

Primary Completion Date

February 10, 2010

Study Completion Date

February 10, 2010

Conditions
Advanced CancerSolid Tumors
Interventions
DRUG

Sodium Stibogluconate

400 mg/m\^2 IV daily on days 1-5.

DRUG

Interferon Alpha-2b

3x10\^6 units subcutaneously three times weekly

Trial Locations (2)

77030

U.T.M.D. Anderson Cancer Center, Houston

87131

University of New Mexico, Albuquerque

All Listed Sponsors
collaborator

VioQuest Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00629200 - Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies | Biotech Hunter | Biotech Hunter